Eli Lilly (LLY) Q3 FY2026 Earnings Overview: Obesity Drug Demand Lifts Guidance in 6.63% Rally
Eli Lilly reported Q3 FY2026 revenue of $24.397 billion versus Reuters/LSEG's $22.61 billion estimate, while its shares rose 6.63% in the completed session. This analysis examines obesity-drug demand, the higher full-year revenue guide, and why acquired research costs lowered the EPS outlook despite stronger underlying sales.